SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis: is there still an indication? Thromb Haemost. 2001; 86: 499508.
  • 2
    Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med. 1996; 125: 17.
  • 3
    Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998; 339: 93104.
  • 4
    Anderson FA Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991; 151: 933938.
  • 5
    Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med. 1992; 232: 155160.
  • 6
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton JM III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998; 158: 585593.
  • 7
    Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost. 2001; 83: 657660.
  • 8
    Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: a risky business. J Gen Intern Med. 1993; 8: 476486.
  • 9
    Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with Stage II breast cancer. N Engl J Med. 1988; 318: 404407.
  • 10
    Pritchard KI. Current and future directions in medical therapy for breast carcinoma. Cancer. 2000; 88: 30653072.
  • 11
    Ellis F. Stilboestrol for advanced breast cancer: a combined investigation. BMJ. 1944; 2: 2021.
  • 12
    Kennedy BJ. Diethylstilbestrol versus testosterone propionate therapy in advanced breast cancer. Surg Gynecol Obstet. 1965; 120: 12461250.
  • 13
    Stoll BA. Progestin therapy of breast cancer: comparison of agents. BMJ. 1967; 3: 338341.
  • 14
    Astra Zeneca. Data on file, Astra Zeneca Pharmaceuticals. Available from URL: www.accessdata.fda.gov/scripts/cder/onctools [accessed June 2004].
  • 15
    Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in post-menopausal women with advanced breast cancer. N Engl J Med. 1981; 304: 1621.
  • 16
    Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996; 348: 11891196.
  • 17
    Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 70,000 women. Lancet. 1992; 339: 7185.
  • 18
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 14511467.
  • 19
    Riggs BL, Hartmann LC. Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med. 2003; 348: 618629.
  • 20
    O'Regan RM, Gradishar WJ. Selective estrogen-receptor modulators in 2001. Oncology (Huntingt). 2001; 15: 11771185, 1189–1190.
  • 21
    Chan S. A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol. 2002; 29(Suppl 11): 129133.
  • 22
    Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001; 28: 291304.
  • 23
    Gradishar WJ, Jordan VC. Hormonal therapy for breast cancer: an update. Hematol Oncol Clin North Am. 1999; 13: 435455.
  • 24
    Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol. 2001; 19: 881894.
  • 25
    Buzdar AU, Robertson JFR, Eiermann W, Nabholtz J-M. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002; 95: 20062016.
  • 26
    Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003; 348: 24312442.
  • 27
    Smith IE. New drugs for breast cancer. Lancet. 2002; 360: 790792.
  • 28
    Sainsbury R. Ovarian ablation in the adjuvant treatment of premenopausal and perimenopausal breast cancer. Br J Surg. 2003; 90: 517526.
  • 29
    Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998; 16: 994999.
  • 30
    Boccardo F, Rubagotti A, Perrota A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol. 1994; 5: 337342.
  • 31
    Nevasaari K, Heikkinen M, Taskinen PJ. Tamoxifen and thrombosis. Lancet. 1978; 1: 946947.
  • 32
    Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep. 1984; 68: 887889.
  • 33
    Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 34
    Veronesi U, Maisonneuve P, Costa A, et al. on behalf of the Italian Tamoxifen Prevention Study. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet. 1998; 352: 9397.
  • 35
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998; 352: 98101.
  • 36
    IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002; 360: 817824.
  • 37
    Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999; 281: 21892197.
  • 38
    Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479484.
  • 39
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996; 88: 15291542.
  • 40
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353: 19932000.
  • 41
    Tormey DC, Gray R, Falkson HC, for the Eastern Cooperative Oncology Group. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst. 1996; 88: 18281833.
  • 42
    Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol. 1991; 9: 286294.
  • 43
    McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ, for the Scottish Cancer Trials Breast Group. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ. 1995; 311: 977980.
  • 44
    Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol. 1998; 45: 608612.
  • 45
    Rutqvist LE, Mattsson A, for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993; 85: 13981406.
  • 46
    Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial. J Clin Oncol. 2000; 18: 27182727.
  • 47
    Holli K, Valavaara R, Blanco G, et al. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. J Clin Oncol. 2000; 18: 34873494.
  • 48
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001; 12: 15271532.
  • 49
    The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 21312139.
  • 50
    Fisher B, Redmond C, Wickerham DL, et al. Doxorubicin-containing regimens for the treatment of Stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol. 1989; 7: 572582.
  • 51
    Fisher B, Redmond C, Legault-Poisson S, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990; 8: 10051018.
  • 52
    Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J, for the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996; 14: 27312737.
  • 53
    Wils JA, Bliss JM, Marty M, et al. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol. 1999; 17: 19881998.
  • 54
    Buzdar AU, Kau S, Hortobagyi GN, et al. Phase I trials of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33: 313316.
  • 55
    Münster PN, Buzdar A, Dhingra K, et al. Phase I study of third-generation selective estrogen receptor modulator, LY353381.HCl, in metastatic breast cancer. J Clin Oncol. 2001; 19: 20022009.
  • 56
    Bellmunt J, Solé L. European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol. 1991; 14(Suppl 2): S36S39.
  • 57
    Haarstad H, Gundersen S, Wist E, Raabe N, Mella O, Kvinnsland S. Droloxifene—a new anti-estrogen: a Phase II study in advanced breast cancer. Acta Oncol. 1992; 31: 425428.
  • 58
    Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter Phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol. 1993; 11: 345350.
  • 59
    Boccardo F, Amoroso D, Iacobelli S, et al. Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients: results of a multicentric Phase II study. Ann Oncol. 1997; 8: 745750.
  • 60
    Jones S, Vogel C, Arkhipov A, et al. Multicenter, Phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol. 1999; 17: 34183425.
  • 61
    Buzdar A, O'Shaughnessy JA, Booser DJ, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003; 21: 10071014.
  • 62
    Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized Phase II multicenter study of exemestane versus tamoxifen as first-line hormone replacement therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003; 14: 13911398.
  • 63
    Allegra JC, Bertino J, Bonomi P, et al. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985; 4(Suppl 6): 6164.
  • 64
    Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995; 13: 25562566.
  • 65
    Pyrhönen S, Valavaara R, Modig H, et al. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomized double-blind, the “Nordic” Phase III study. Br J Cancer. 1997; 76: 270277.
  • 66
    Milla-Santos A, Milla L, Rallo L, Solano V. Phase III randomized trial of toremifene versus tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat. 2001; 65: 119124.
  • 67
    Buzdar A, Hayes D, El-Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002; 73: 161175.
  • 68
    Arpino G, Krishnan MN, Dinesh CD, Bardou VJ, Clark GM, Elledge RM. Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. Ann Oncol. 2003; 233241.
  • 69
    Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. J Clin Oncol. 1996; 14: 20002011.
  • 70
    Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A, for the Arimidex Study Group. A phase III trials comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer. Cancer. 1997; 79: 730739.
  • 71
    Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol. 1998; 9: 639645.
  • 72
    Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998; 16: 453461.
  • 73
    Thürlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: prospective randomized trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol. 1996; 7: 471479.
  • 74
    Bonneterre J, Thürlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 2000; 18: 37483757.
  • 75
    Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 2000; 18: 37583767.
  • 76
    Mouridsen H, Gershanovich M, Sun Y, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001; 19: 25962606.
  • 77
    Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003; 21: 21012109.
  • 78
    Milla-Santos A, Milla L, Portella J, et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer. Am J Clin Oncol. 2003; 26: 317322.
  • 79
    Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine therapy. J Clin Oncol. 2002; 20: 33963403.
  • 80
    Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002; 20: 33863395.
  • 81
    Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer. 2003; 39: 23182327.
  • 82
    Haeger K. Problems of acute deep venous thrombosis. I: the interpretation of signs and symptoms. Angiology. 1969; 20: 219223.
  • 83
    Hull RD, Raskob GE, Leclerc JR, Jay RM, Hirsh J. The diagnosis of suspected venous thrombosis. Clin Chest Med. 1984; 5: 439456.
  • 84
    Modan B, Sharon E, Jelin N. Factors contributing to the incorrect diagnosis of pulmonary embolic disease. Chest. 1972; 62: 388393.
  • 85
    Poulose KP, Reba RC, Gilday DL, Deland FH, Wagner HN. Diagnosis of pulmonary embolism. A correlative study of the clinical, scan and angiographic findings. BMJ. 1970; 3: 6771.
  • 86
    Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002; 22: 201210.
  • 87
    Cuzick JH, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003; 361: 296300.
  • 88
    Duggan C, Marriot K, Edwards R, Cuzick J. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003; 21: 35883593.
  • 89
    Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349: 17931802.
  • 90
    Gomes MPV, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Huntingt). 2003; 17: 126135, 139.
  • 91
    Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat. 2001; 65: 125134.
  • 92
    Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med. 2000; 132: 689696.
  • 93
    Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994; 344: 14531457.
  • 94
    Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost. 1998; 79: 2831.
  • 95
    Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep venous thrombosis. Arterioscler Thromb Vasc Biol. 1999; 19: 700703.
  • 96
    Pabinger I, Schneider B, and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost. 1994; 71: 548552.
  • 97
    Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002; 116: 851854.
  • 98
    Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterisocler Thromb Vasc Biol. 2002; 22: 10121017.
  • 99
    Høibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Thromb Haemost. 2000; 84: 961967.